Affimed (0HL9) Stock Overview
A clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
0HL9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Affimed N.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$1.12 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 9,900.00% |
| 3 Month Change | 0% |
| 1 Year Change | -99.90% |
| 3 Year Change | -99.90% |
| 5 Year Change | -99.90% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HL9 | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | -50.0% | -2.1% | -0.7% |
| 1Y | -99.9% | 37.8% | 26.1% |
Return vs Industry: 0HL9 underperformed the UK Biotechs industry which returned 40.4% over the past year.
Return vs Market: 0HL9 underperformed the UK Market which returned 28.1% over the past year.
Price Volatility
| 0HL9 volatility | |
|---|---|
| 0HL9 Average Weekly Movement | 10,944.5% |
| Biotechs Industry Average Movement | 8.2% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in GB Market | 11.9% |
| 10% least volatile stocks in GB Market | 3.2% |
Stable Share Price: 0HL9's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: 0HL9's weekly volatility has increased from 4909% to 10945% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | www.affimed.com |
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors.
Affimed N.V. Fundamentals Summary
| 0HL9 fundamental statistics | |
|---|---|
| Market cap | US$1.64k |
| Earnings (TTM) | -US$82.05m |
| Revenue (TTM) | US$6.61m |
Is 0HL9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HL9 income statement (TTM) | |
|---|---|
| Revenue | €5.64m |
| Cost of Revenue | €0 |
| Gross Profit | €5.64m |
| Other Expenses | €75.61m |
| Earnings | -€69.97m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did 0HL9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/21 17:46 |
| End of Day Share Price | 2026/04/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Affimed N.V. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Birchenough | BMO Capital Markets Equity Research |
| Brian Abrahams | Jefferies LLC |
| Daina Graybosch | Leerink Partners LLC |